Join
Live feed
·
PRReleasevia Quantisnow
Mirum Pharmaceuticals Inc. logo
Travere Therapeutics Inc. logo

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

ByQuantisnow·Wall Street's wire, on your screen.
MIRM· Mirum Pharmaceuticals Inc.TVTX· Travere Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MIRM (Mirum Pharmaceuticals Inc.), TVTX (Travere Therapeutics Inc.) and more on Quantisnow.